8-K: Pluri Inc. Faces Nasdaq Delisting Notice Due to Equity Shortfall

Pluri Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Summary

• Pluri Inc. has been notified by Nasdaq that it does not meet the minimum stockholders' equity requirement of $2.5 million for continued listing.
• The company also does not meet the alternative listing standards related to market value of listed securities or net income.
• Pluri has 45 days to submit a plan to regain compliance.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 days to demonstrate compliance.
• If the plan is not accepted or compliance is not achieved within the extension period, Pluri may request a hearing before an independent panel.
• The company intends to take all reasonable measures to regain compliance and remain listed on Nasdaq.
• There is no guarantee that Nasdaq will grant an extension or that Pluri will regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting notice, but the company is taking steps to address the issue. The uncertainty of the outcome and the potential for delisting contribute to the low sentiment score.

Positives

• Pluri intends to submit a plan to regain compliance within the 45-day period.
• The company has the option to request a hearing before an independent panel if its plan is not accepted or if it fails to regain compliance within the extension period.
• The company's shares will continue to trade on The Nasdaq Capital Market while it works to regain compliance.

Negatives

• Pluri is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• The company also failed to meet alternative listing standards related to market value of listed securities or net income.
• There is no assurance that Nasdaq will grant an extension or that Pluri will ultimately regain compliance.

Risks

• There is a risk that Nasdaq may not accept Pluri's plan to regain compliance.
• Pluri may not be able to regain compliance within the given time frame, potentially leading to delisting.
• The company faces risks related to technology changes, clinical trial delays, regulatory approvals, and competition.
• The company's products may not be approved by regulatory agencies, its technology may not be validated, and its methods may not be accepted by the scientific community.
• The company may be unable to retain or attract key employees, and unforeseen scientific difficulties may develop with its processes.

Future Outlook

Pluri intends to submit a plan to regain compliance with Nasdaq listing requirements, but there is no guarantee of success. The company will continue to trade on Nasdaq while it works to regain compliance.

Management Comments

• The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.

Industry Context

This announcement highlights the challenges faced by companies in maintaining listing requirements, particularly those in the biotechnology sector which can be capital intensive and have long development cycles. It is not uncommon for companies to receive deficiency notices from exchanges, and the outcome depends on their ability to address the issues and demonstrate compliance.

Comparison to Industry Standards

• Many biotech companies face challenges in maintaining Nasdaq listing requirements due to the capital-intensive nature of research and development.
• Companies like Cellectis and Athersys have also faced similar delisting notices in the past, highlighting the commonality of this issue in the sector.
• The ability to raise capital and achieve profitability is crucial for maintaining listing status, and Pluri's situation is not unique in this regard.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decrease in share value.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Pluri will submit a plan to regain compliance within 45 days.
• Nasdaq will review the plan and may grant an extension of up to 180 days.
• Pluri may request a hearing before an independent panel if its plan is not accepted or if it fails to regain compliance within the extension period.

Key Dates

Keywords

Nasdaq, delisting, stockholders' equity, compliance, listing rules, PLUR, deficiency letter